An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 272
- Registration Number
- NCT01064414
The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 285
- Registration Number
- NCT01063881
A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 546
- Registration Number
- NCT01051531
CANVAS - CANagliflozin cardioVascular Assessment Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 4330
- Registration Number
- NCT01032629
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 79
- Registration Number
- NCT01024036
An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 10027
- Registration Number
- NCT01021670
A First in Man Study of MABp1 in Patients With Advanced Cancers
- First Posted Date
- 2009-11-26
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT01021072
- Locations
- 🇺🇸
M.D. Anderson Cancer Institute, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01017939
- Locations
- 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇨🇦BC Cancer Agency, Vancouver, British Columbia, Canada
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 228
- Registration Number
- NCT01009047
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 615
- Registration Number
- NCT01009086
© Copyright 2024. All Rights Reserved by MedPath